Create Account | Sign In: Author or Forum

Search Symptoms

Medical Specialty >> Pharmacy

Fentanyl Now the No. 1 Opioid OD Killer

9:00 AM CST. By Steven Reinberg
HealthDay Reporter Read article More Pharmacy News

JOURNAL UPDATE

Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease

12:00 PM CST. CT-P13 is equivalent to reference product in primary outcome; no difference in safety outcomes

MONTHLY JOURNAL SUMMARY

November 2018 Briefing - Pharmacy

December 03, 2018. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.


FEATURED ARTICLES

Robert L. Coleman, MD's avatarRucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial

Robert L. Coleman, MD. Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…

Ted Lain, MD's avatarInvestigational Topical Minocycline Gel for Acne Advances to Phase III Development

Ted Lain, MD. Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…

Dr. Alberto De la Guerra's avatarBevacizumab for breast cancer: FDA grants a stay of execution

Dr. Alberto De la Guerra. The Food and Drug Administration has after repeated delays proposed removing metastatic breast cancer as an indication from the Avastin label. The proposal is being contested by Roche/Genentech, the drug’s maker. In this article we review the evidence for and against this decision.


MEDICAL FOCUS

DISCUSSION

RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development

By MrRobin

Great articles. learnt a lot from it.

ANNOUNCEMENTS